Increase Your Insulin Glargine Dose and Discontinue Glipizide
For uncontrolled blood sugars on glipizide 10 mg daily, sliding scale humalog, and glargine 45 units daily, you should increase your basal insulin glargine dose using an evidence-based titration algorithm and strongly consider discontinuing the glipizide, as sliding scale insulin alone is ineffective and the combination suggests inadequate basal coverage. 1
Immediate Action: Titrate Basal Insulin Aggressively
Your current regimen indicates basal insulin failure—you're already on 45 units of glargine yet still requiring sliding scale corrections, which signals inadequate basal coverage rather than prandial insulin needs.
Recommended titration approach:
- Increase glargine by 2 units every 3 days until fasting blood glucose reaches ≤100 mg/dL (≤5.5 mmol/L) 1
- If fasting glucose remains ≥180 mg/dL (≥10 mmol/L), consider more aggressive increases of 4-6 units every 3 days 1
- Recent evidence suggests that 44-100% increases in total daily insulin dose are significantly more effective than the traditional 10-22% increases for achieving glycemic control 2
Critical monitoring: If hypoglycemia occurs (glucose <70 mg/dL), reduce the dose by 10-20% and reassess 1
Discontinue Glipizide
Glipizide should be discontinued once you're on adequate basal insulin. The evidence is clear:
- Sulfonylureas like glipizide provide minimal additional benefit when combined with insulin doses >20 mg daily 3
- Sliding scale insulin alone (without adequate basal coverage) is associated with a 3-fold higher risk of hyperglycemic episodes compared to no pharmacologic therapy 4
- The combination of glipizide with inadequate basal insulin creates unnecessary hypoglycemia risk without improving control 3
Transition from Sliding Scale to Structured Prandial Insulin
Once your fasting glucose is controlled on optimized basal insulin, if A1C remains above goal:
Add scheduled prandial insulin rather than relying on sliding scale:
- Start with 4 units of humalog before your largest meal or 10% of your basal dose 1
- Titrate by 1-2 units or 10-15% every 3 days based on 2-hour post-meal glucose 1
- The RABBIT 2 trial demonstrated that basal-bolus regimens achieve target glucose <140 mg/dL in 66% of patients versus only 38% with sliding scale alone 5
Consider GLP-1 Receptor Agonist
Before intensifying to full basal-bolus insulin, strongly consider adding a GLP-1 receptor agonist (like semaglutide or dulaglutide) if not contraindicated 1. This approach:
- Reduces cardiovascular and mortality risk
- Provides additional A1C lowering of 1.5-2.0%
- Minimizes weight gain and hypoglycemia risk
- May reduce your total insulin requirements
Common Pitfalls to Avoid
Don't continue sliding scale as monotherapy—it's associated with worse outcomes and provides reactive rather than proactive glucose management 4
Don't undertitrate basal insulin—if you're still needing frequent sliding scale corrections, your basal dose is insufficient. The median effective dose in clinical trials is 0.43-0.50 units/kg 6
Don't keep glipizide "just in case"—it adds hypoglycemia risk without benefit once you're on adequate insulin 3
Assess for "overbasalization"—if your bedtime-to-morning glucose differential is high or you have significant post-meal spikes despite controlled fasting glucose, you need prandial insulin, not more basal insulin 1
Practical Algorithm
- Week 1-2: Increase glargine by 2-6 units every 3 days targeting fasting glucose ≤100 mg/dL
- Week 2: Discontinue glipizide once glargine >50-60 units or fasting glucose controlled
- Week 3-4: If A1C remains elevated despite controlled fasting glucose, add scheduled prandial humalog (not sliding scale) with largest meal
- Ongoing: Consider GLP-1 RA addition before progressing to full basal-bolus regimen